Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Acebes Huerta, Andrea ^a   Huergo Zapico, Leticia ^a   Gonzalez Rodriguez, Ana Pilar ^b   Fernandez Guizan, Azahara ^a   Payer, Angel R ^b   López Soto, Alejandro ^a   Gonzalez, Segundo ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; INTERLEUKIN 2; LENALIDOMIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; RITUXIMAB; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEIOTROPY; PROTEIN EXPRESSION; T CELL DEPLETION; TUMOR IMMUNITY; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE SUBPOPULATION; PATHOLOGY; TUMOR CELL CULTURE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; IMMUNOMODULATION; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE SUBSETS; THALIDOMIDE; TUMOR CELLS, CULTURED;

EID: 84929235609     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/265840     Document Type: Article

References (30)

1. L. Huergo-Zapico, A. P. Gonzalez-Rodriguez, J. Contesti, A. Fernandez-Guizan, A. Acebes Huerta, and S. Gonzalez, "Immune response and immunotherapy in chronic lymphocytic leukemia, " in Chronic Lymphocytic Leukemia, pp. 978-953, InTech, Rijeka, Croatia, 2011.
2. J. B. Swann andM. J. Smyth, "Immune surveillance of tumors, " Journal of Clinical Investigation, vol. 117, no. 5, pp. 1137-1146, 2007.
3. M. J. Smyth, G. P. Dunn, and R. D. Schreiber, "Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity, " Advances in Immunology, vol. 90, pp. 1-50, 2006.
4. A. Poggi, C. Venturino, S. Catellani et al., "Vδ1 T lymphocytes fromB-CLL patients recognizeULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid, " Cancer Research, vol. 64, no. 24, pp. 9172-9179, 2004.
5. A. P. Gonzalez-Rodriguez, J. Contesti, L. Huergo-Zapico et al., "Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia, " Leukemia & Lymphoma, vol. 51, no. 10, pp. 1829-1836, 2010.
6. A. D. Hamblin and T. J. Hamblin, "The immunodeficiency of chronic lymphocytic leukaemia, " The British Medical Bulletin, vol. 87, no. 1, pp. 49-62, 2008.
7. A. R. Jazirehi and B. Bonavida, "Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkins lymphoma: Implications in chemosensitization and therapeutic intervention, " Oncogene, vol. 24, no. 13, pp. 2121-2143, 2005.
8. F. J. Hernandez-Ilizaliturri, N. Reddy, B. Holkova, E. Ottman, and M. S. Czuczman, "Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model, " Clinical Cancer Research, vol. 11, no. 16, pp. 5984-5992, 2005.
9. P. G. Richardson, E. Blood, C. S. Mitsiades et al., "A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma, " Blood, vol. 108, no. 10, pp. 3458-3464, 2006.
10. A. List, S. Kurtin, D. J. Roe et al., "Efficacy of lenalidomide in myelodysplastic syndromes, " The New England Journal of Medicine, vol. 352, no. 6, pp. 549-557, 2005.
11. A. Chanan-Khan, K. C. Miller, L. Musial et al., "Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study, " Journal of Clinical Oncology, vol. 24, no. 34, pp. 5343-5349, 2006.
12. T. Sher, K. C. Miller, D. Lawrence et al., "Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics, " Leukemia and Lymphoma, vol. 51, no. 1, pp. 85-88, 2010.
13. A. Ferrajoli, B. N. Lee, E. J. Schlette et al., "Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia, " Blood, vol. 111, no. 11, pp. 5291-5297, 2008.
14. A. P. Gonzalez-Rodriguez, A. R. Payer, A. Acebes-Huerta et al., "Lenalidomide and chronic lymphocytic leukemia, " BioMed Research International, vol. 2013, Article ID 932010, 9 pages, 2013.
15. C. S. Mitsiades, N. S. Mitsiades, P. G. Richardson, N. C. Munshi, and K. C. Anderson, "Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment, " Journal of Cellular Biochemistry, vol. 101, no. 4, pp. 950-968, 2007.
16. A. Pellagatti, M. Jadersten, A.-M. Forsblom et al., "Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 27, pp. 11406-11411, 2007.
17. A. A. Chanan-Khan, K. Chitta, N. Ersing et al., "Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response, " British Journal of Haematology, vol. 155, no. 4, pp. 457-467, 2011.
18. G. Aue, N. Njuguna, X. Tian et al., "Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia, " Haematologica, vol. 94, no. 9, pp. 1266-1273, 2009.
19. B.-N. Lee, H. Gao, E. N. Cohen et al., "Treatmentwith lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia, " Cancer, vol. 117, no. 17, pp. 3999-4008, 2011.
20. D. H. Chang, N. Liu, V. Klimek et al., "Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications, " Blood, vol. 108, no. 2, pp. 618-621, 2006.
21. D. I. Godfrey, H. R. MacDonald, M. Kronenberg, M. J. Smyth, and L. Van Kaer, "NKT cells: whats in a name?" Nature Reviews Immunology, vol. 4, no. 3, pp. 231-237, 2004.
22. A. G. Ramsay, A. J. Johnson, A. M. Lee et al., "Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug, " Journal of Clinical Investigation, vol. 118, no. 7, pp. 2427-2437, 2008.
23. F. T. Awan, A. J. Johnson, R. Lapalombella et al., "Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia, " Leukemia and Lymphoma, vol. 51, no. 1, pp. 27-38, 2010.
24. V. Kotla, S. Goel, S. Nischal et al., "Mechanism of action of lenalidomide in hematological malignancies, " Journal of Hematology and Oncology, vol. 2, no. 12, article 36, 2009.
25. L. Wu, M. Adams, T. Carter et al., "Lenalidomide enhances natural killer cell andmonocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells, " Clinical Cancer Research, vol. 14, no. 14, pp. 4650-4657, 2008.
26. J. B. Bartlett, "Lenalidomide enhances tumor killing in vitro during ADCC mediated by Trastuzumab, Cetuximab, and Rituximab, " Journal of Clinical Oncology, vol. 25, p. 3023, 2007.
27. A. Chanan-Khan, K. C. Miller, D. Lawrence et al., "Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response, " Cancer, vol. 117, no. 10, pp. 2127-2135, 2011.
28. M. Hallek, B. D. Cheson, D. Catovsky et al., "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines, " Blood, vol. 111, no. 12, pp. 5446-5456, 2008.
29. T. Hayashi, T. Hideshima, M. Akiyama et al., "Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application, " The British Journal of Haematology, vol. 128, no. 2, pp. 192-203, 2005.
30. A. Lopez-Soto, A. R. Folgueras, E. Seto, and S. Gonzalez, "HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer, " Oncogene, vol. 28, no. 25, pp. 2370-2382, 2009.